S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20

Alimera Sciences Stock Forecast, Price & News

-0.51 (-8.81%)
(As of 11/26/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
43,667 shs
Average Volume
61,608 shs
Market Capitalization
$36.63 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive ALIM News and Ratings via Email

Sign-up to receive the latest news and ratings for Alimera Sciences and its competitors with MarketBeat's FREE daily newsletter.

Alimera Sciences logo

About Alimera Sciences

Alimera Sciences, Inc. engages in the research and development of biopharmaceutical products. It operates through the following geographical segments: U.S. and International. The firm focuses on the development of ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration and retinal vein occlusion. Its products include ILUVIEN and NADPH Oxidase Inhibitors. The company was founded by Daniel C. Myers and David R. Holland on June 4, 2003 and is headquartered in Alpharetta, GA.


Alimera Sciences Continues Bullish Trend
November 5, 2021 |  nasdaq.com
Alimera Sciences, Inc. (NASDAQ:ALIM) CEO Buys $124,622.25 in Stock
November 4, 2021 |  americanbankingnews.com
Alimera Sciences earnings: here's what to expect
November 2, 2021 |  markets.businessinsider.com
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$50.82 million
Book Value
($2.55) per share


Net Income
$-5.34 million
Pretax Margin




Free Float
Market Cap
$36.63 million

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)

Social Links


Overall MarketRank

2.20 out of 5 stars

Medical Sector

358th out of 1,392 stocks

Pharmaceutical Preparations Industry

167th out of 670 stocks

Analyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -

Alimera Sciences (NASDAQ:ALIM) Frequently Asked Questions

Is Alimera Sciences a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Alimera Sciences in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Alimera Sciences stock.
View analyst ratings for Alimera Sciences
or view top-rated stocks.

How has Alimera Sciences' stock price been impacted by Coronavirus (COVID-19)?

Alimera Sciences' stock was trading at $5.24 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ALIM shares have increased by 0.8% and is now trading at $5.28.
View which stocks have been most impacted by COVID-19

When is Alimera Sciences' next earnings date?

Alimera Sciences is scheduled to release its next quarterly earnings announcement on Wednesday, February 23rd 2022.
View our earnings forecast for Alimera Sciences

How were Alimera Sciences' earnings last quarter?

Alimera Sciences, Inc. (NASDAQ:ALIM) posted its quarterly earnings results on Wednesday, October, 27th. The biopharmaceutical company reported ($0.60) earnings per share for the quarter, missing analysts' consensus estimates of ($0.52) by $0.08. The biopharmaceutical company earned $12.15 million during the quarter, compared to the consensus estimate of $12.30 million. Alimera Sciences had a negative net margin of 2.11% and a negative trailing twelve-month return on equity of 1.30%. During the same period in the prior year, the company posted ($0.12) EPS.
View Alimera Sciences' earnings history

When did Alimera Sciences' stock split? How did Alimera Sciences' stock split work?

Shares of Alimera Sciences reverse split before market open on Friday, November 15th 2019. The 1-15 reverse split was announced on Thursday, November 7th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, November 14th 2019. An investor that had 100 shares of Alimera Sciences stock prior to the reverse split would have 7 shares after the split.

What price target have analysts set for ALIM?

2 equities research analysts have issued twelve-month price targets for Alimera Sciences' shares. Their forecasts range from $12.00 to $14.50. On average, they anticipate Alimera Sciences' share price to reach $13.25 in the next year. This suggests a possible upside of 150.9% from the stock's current price.
View analysts' price targets for Alimera Sciences
or view top-rated stocks among Wall Street analysts.

Who are Alimera Sciences' key executives?

Alimera Sciences' management team includes the following people:

What is Rick Eiswirth's approval rating as Alimera Sciences' CEO?

2 employees have rated Alimera Sciences CEO Rick Eiswirth on Glassdoor.com. Rick Eiswirth has an approval rating of 100% among Alimera Sciences' employees. This puts Rick Eiswirth in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Alimera Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alimera Sciences investors own include EyePoint Pharmaceuticals (EYPT), OPKO Health (OPK), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Advanced Micro Devices (AMD), Amarin (AMRN), AngloGold Ashanti (AU), SSR Mining (SSRM), ADMA Biologics (ADMA) and Cellectar Biosciences (CLRB).

What is Alimera Sciences' stock symbol?

Alimera Sciences trades on the NASDAQ under the ticker symbol "ALIM."

Who are Alimera Sciences' major shareholders?

Alimera Sciences' stock is owned by a variety of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (2.04%), Ensign Peak Advisors Inc (0.28%), Dimensional Fund Advisors LP (0.16%), Optimum Investment Advisors (0.12%) and Concourse Financial Group Securities Inc. (0.00%). Company insiders that own Alimera Sciences stock include James R Largent, John Philip Jones, Philip Ashman and Richard S Eiswirth Jr.
View institutional ownership trends for Alimera Sciences

Which institutional investors are selling Alimera Sciences stock?

ALIM stock was sold by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, and Renaissance Technologies LLC.
View insider buying and selling activity for Alimera Sciences
or view top insider-selling stocks.

Which institutional investors are buying Alimera Sciences stock?

ALIM stock was purchased by a variety of institutional investors in the last quarter, including Ensign Peak Advisors Inc, and Optimum Investment Advisors. Company insiders that have bought Alimera Sciences stock in the last two years include James R Largent, John Philip Jones, and Richard S Eiswirth Jr.
View insider buying and selling activity for Alimera Sciences
or or view top insider-buying stocks.

How do I buy shares of Alimera Sciences?

Shares of ALIM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Alimera Sciences' stock price today?

One share of ALIM stock can currently be purchased for approximately $5.28.

How much money does Alimera Sciences make?

Alimera Sciences has a market capitalization of $36.63 million and generates $50.82 million in revenue each year. The biopharmaceutical company earns $-5.34 million in net income (profit) each year or ($0.38) on an earnings per share basis.

How many employees does Alimera Sciences have?

Alimera Sciences employs 135 workers across the globe.

When was Alimera Sciences founded?

Alimera Sciences was founded in 2003.

What is Alimera Sciences' official website?

The official website for Alimera Sciences is www.alimerasciences.com.

Where are Alimera Sciences' headquarters?

Alimera Sciences is headquartered at 6120 WINDWARD PARKWAY STE 290, ALPHARETTA GA, 30005.

How can I contact Alimera Sciences?

Alimera Sciences' mailing address is 6120 WINDWARD PARKWAY STE 290, ALPHARETTA GA, 30005. The biopharmaceutical company can be reached via phone at (678) 990-5740, via email at [email protected], or via fax at 678-990-5744.

This page was last updated on 11/27/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.